Abecma

Indications for Use

Abecma is used for the treatment of multiple myeloma in adult patients. It is specifically indicated for cases where the cancer is:

• Relapsed: The cancer came back after a period of improvement.
• Refractory: The cancer did not respond to previous medical treatments.

This medication is used after a patient has already tried several other types of therapy. Healthcare providers typically prescribe Abecma only after the patient has received multiple prior lines of treatment, which must include specific classes of drugs such as immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies.

Because this is a specialized immunotherapy, it is reserved for patients whose cancer has progressed despite these previous standard treatments.

Personalized Immunotherapy

Abecma is a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy. It is a personalized medicine made from a patient's own white blood cells, specifically T cells, which are responsible for fighting infections and other diseases.

Targeting Multiple Myeloma

The treatment works by targeting a specific protein called B-cell maturation antigen (BCMA). This protein is found on the surface of both healthy and cancerous plasma cells, but it is especially prevalent in patients with multiple myeloma.

The process of creating and using Abecma involves several steps:

• Collection: T cells are removed from the patient's blood through a process called leukapheresis.
• Modification: In a laboratory, a new gene is added to these T cells. This gene gives the cells the ability to produce CAR proteins on their surface.
• Recognition: These CAR proteins act like a navigation system, allowing the T cells to identify and latch onto the BCMA protein on cancer cells.
• Elimination: After the modified cells are infused back into the patient, they seek out the cancer cells. When they connect with the BCMA protein, the T cells are activated to kill the cancer cells and begin to multiply within the body to continue the attack.

Common Side Effects

The most common side effects associated with Abecma treatment include:

• Feeling very tired or weak
• Fever and chills
• Nausea, diarrhea, or constipation
• Muscle or joint pain
• Headache
• Cough or difficulty breathing
• Decreased appetite
• Dizziness
• Swelling, especially in the legs or hands

Serious Side Effects

Some side effects require immediate medical intervention. These include:

• Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause high fever, low blood pressure, and difficulty breathing.
• Neurologic Problems: Symptoms such as confusion, seizures, tremors, or trouble speaking.
• Severe Infections: A weakened immune system can lead to serious or life-threatening infections.
• Low Blood Cell Counts: Prolonged periods of low white blood cells, red blood cells, or platelets, which can increase the risk of bleeding or infection.
• Hypogammaglobulinemia: Low levels of antibodies in the blood, which may require additional treatment.

Healthcare providers will monitor patients closely for several weeks following the infusion to identify and manage these side effects early.

Boxed Warnings

Abecma carries a boxed warning for several serious and potentially life-threatening conditions. Healthcare providers monitor patients closely for these reactions during and after treatment.

• Cytokine Release Syndrome (CRS): This is a systemic inflammatory response that can cause high fever, chills, low blood pressure, and difficulty breathing.
• Neurologic Toxicities: Patients may experience confusion, seizures, tremors, or difficulty speaking. These effects can be severe or life-threatening and may occur alongside or independently of CRS.
• Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): This is a severe immune system overreaction that can lead to organ failure.
• Prolonged Cytopenia: This involves a significant and lasting drop in blood cell counts, which can increase the risk of bleeding and infection for several weeks or months.

Secondary Malignancies

There is a risk of developing new cancers, including T-cell malignancies, after treatment with Abecma. Because this is a gene therapy, patients are typically monitored for life to detect the development of any new cancers.

Infections and Immune System Effects

Treatment can lead to severe or life-threatening infections. It may also cause hypogammaglobulinemia, a condition where the body does not produce enough antibodies. This may require supplemental treatment with immunoglobulin to help prevent infections.

Monitoring and Safety Precautions

Due to the risk of serious side effects, specific safety measures are required for patients receiving this therapy:

• Patients must stay within a certain distance of the treatment center for at least four weeks after receiving the infusion to ensure rapid access to specialized care.
• Driving or operating heavy machinery is generally discouraged for at least eight weeks following treatment due to the risk of sudden neurologic changes or decreased alertness.
• Live virus vaccines should not be administered for a period before and after treatment, as the immune system may be too weak to respond safely.

Pregnancy

It is not known whether Abecma can cause harm to an unborn baby. There are no clinical trials or studies involving pregnant women, and animal reproduction studies have not been conducted for this medication. Because the risks to a developing fetus are unknown, healthcare providers typically require a pregnancy test for individuals of childbearing potential before beginning the treatment process.

Breastfeeding

There is no data regarding the presence of Abecma in human breast milk, its effects on a breastfed infant, or its impact on milk production. Because the potential for adverse reactions in a nursing child is unknown, it is important to discuss the risks and benefits of breastfeeding with a healthcare provider before starting treatment.

Dosage Forms

Abecma is an autologous (patient-specific) cell suspension. This means the medication is custom-made for each individual using their own white blood cells, which are collected and genetically modified in a laboratory before being returned to the patient.

It is administered as a single-dose intravenous infusion by a healthcare professional in a clinical setting.

Strengths and Packaging

This medication is supplied in one or more infusion bags. Each bag contains a frozen suspension of genetically modified T cells. Because the treatment is manufactured specifically for each patient, the total volume and the number of bags used for the infusion can vary.

• Form: Intravenous infusion (suspension).
• Dosing: Single-dose treatment based on the number of modified cells.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel) for the treatment of adults with relapsed or refractory multiple myeloma. It is specifically indicated for patients who have already received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Boxed Warning

Abecma carries a Boxed Warning, the FDA’s most serious type of warning, due to the risk of severe and potentially life-threatening side effects, including:

• Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause high fever and organ dysfunction.
• Neurologic Toxicities: Also known as Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can cause confusion, seizures, or loss of consciousness.
• Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS): A severe immune system overreaction.
• Prolonged Cytopenia: Significantly low blood cell counts that last for several weeks after the infusion.

Risk Evaluation and Mitigation Strategy (REMS)

Because of these serious risks, the FDA requires a restricted program called the Abecma REMS. This program ensures that the therapy is only dispensed by certified healthcare facilities that are trained to recognize and manage severe side effects. Patients must be monitored daily for at least seven days following the infusion at the certified facility and must stay near the facility for at least four weeks.

Safety Communications

The FDA has issued communications regarding the risk of developing new blood cancers (T-cell malignancies) after treatment with CAR T-cell therapies like Abecma. While the FDA has determined that the overall benefits of these treatments outweigh the risks for their approved uses, the agency requires lifelong monitoring for new cancers in patients who receive these therapies.

Factors Influencing Cost

The cost of Abecma can vary significantly based on several factors. Because it is a personalized CAR-T cell therapy, the process involves collecting a patient's own immune cells, modifying them in a laboratory, and infusing them back into the patient. This complex process requires specialized medical facilities and highly trained staff.

Additional costs often associated with Abecma treatment include:

• Pre-treatment procedures: This includes chemotherapy (lymphodepletion) given before the infusion to prepare the body for the modified cells.
• Hospitalization: Patients are typically required to stay in or near a certified treatment center for several weeks to monitor for serious side effects like cytokine release syndrome (CRS).
• Long-term monitoring: Frequent follow-up appointments are necessary for several months to check for delayed reactions or complications.

Insurance and Financial Assistance

Most private insurance plans, as well as Medicare and Medicaid, may cover Abecma if specific medical criteria are met. However, insurance companies usually require prior authorization before the treatment process can begin.

The manufacturer may offer support programs to help patients navigate insurance coverage or provide financial assistance for those who qualify. Because Abecma is only available through a restricted program at specialized centers, patients and caregivers should speak with the financial counselor at their authorized treatment center. These counselors can help explore available options, including assistance with travel and lodging expenses if the treatment center is far from the patient's home.